Zoetis Receives Emergency Use Authorization for Simparica Trio® (sarolaner, moxidectin, and pyrantel chewable tablets) for Treatment of New World Screwworm Infestations in Dogs and Puppies
Go back to Zoetis Receives Emergency Use Authorization for Simparica Trio® (sarolaner, moxidectin, and pyrantel chewable tablets) for Treatment of New World Screwworm Infestations in Dogs and Puppies| Zoetis (NYSE: ZTS) | Delayed: 73.56 -2.25 (2.97%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $75.81 | 52 Week High | $53.14 | |||
| Open | $74.80 | 52 Week Low | $38.26 | |||
| Day High | $75.10 | P/E | 72.83 | |||
| Day Low | $73.48 | EPS | $1.01 | |||
| Volume | 5,658,392 | |||||
